{"id":855,"date":"2026-10-20T03:32:18","date_gmt":"2026-10-20T01:32:18","guid":{"rendered":"http:\/\/novameds.local\/de\/?post_type=product&#038;p=855"},"modified":"2026-10-20T04:00:41","modified_gmt":"2026-10-20T02:00:41","slug":"catalog-oxiracetam-powder-50-grams","status":"publish","type":"product","link":"https:\/\/novameds.health\/de\/produkt\/catalog-oxiracetam-powder-50-grams\/","title":{"rendered":"Oxiracetam \u2013 Powder, 50 grams"},"content":{"rendered":"<section id=\"composition\" data-nav=\"Zusammensetzung und Produktdetails\">\n<h2>Zusammensetzung und Produktdetails<\/h2>\n<div class=\"nm-catalog-document\">\n<div>\n<h2>\u00dcbersicht<\/h2>\n<div>\n<p>Oxiracetam is a hydroxylated pyrrolidinone derivative within the racetam structural class, distinguished from piracetam by a 4-hydroxy substitution on the pyrrolidinone ring. Research interest centers on its proposed effects on glutamatergic AMPA receptor signalling and cholinergic pathway modulation in neuronal models.<\/p>\n<p>Research applications include racetam structure-activity relationship studies, AMPA receptor pharmacology, and comparative pyrrolidinone-class compound research.<\/p>\n<ul>\n<li> <span><b>High Purity<\/b> \u2013 99% Purity Guaranteed<\/span><\/li>\n<li> Independently Lab Tested<\/li>\n<li> Research Grade Quality<\/li>\n<li> For Laboratory Research Use Only<\/li>\n<\/ul><\/div>\n<div>\n<p><a href=\"https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/4626\" target=\"_blank\" rel=\"noopener noreferrer\">Molekulardaten bei PubChem<\/a><\/p>\n<\/p><\/div>\n<\/p><\/div>\n<div>\n<h2>Eigenschaften<\/h2>\n<div class=\"nm-catalog-table\" tabindex=\"0\" role=\"region\" aria-label=\"Product data\">\n<table>\n<tbody>\n<tr>\n<th>Chemical Formula<\/th>\n<td>C6H10N2O3<\/td>\n<\/tr>\n<tr>\n<th>Synonyms<\/th>\n<td>oxiracetam 62613-82-5, 2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetamide, 4-Hydroxy-2-oxopyrrolidine-N-acetamide, ISF 2522<\/td>\n<\/tr>\n<tr>\n<th>Molar Mass<\/th>\n<td>158.16 g\/mol<\/td>\n<\/tr>\n<tr>\n<th>CAS Number<\/th>\n<td>62613-82-5<\/td>\n<\/tr>\n<tr>\n<th>PubChem CID<\/th>\n<td>4626<\/td>\n<\/tr>\n<tr>\n<th>Total Compound Content<\/th>\n<td>50 grams<\/td>\n<\/tr>\n<tr>\n<th>Shelf Life<\/th>\n<td>36 months<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div><\/div>\n<div>\n<h2>Forschung<\/h2>\n<p>\t\t\t\t\t<span>Oxiracetam is studied within the racetam family for its hydroxyl-substituted pyrrolidinone structure, a modification relative to the parent compound piracetam that is investigated for altered pharmacological profile. Proposed mechanisms under research include modulation of glutamatergic transmission via AMPA-type ionotropic glutamate receptors and influence on high-affinity choline uptake in cholinergic synaptic models, positioning oxiracetam as a tool compound for dissecting overlapping glutamatergic and cholinergic contributions to racetam-class pharmacology. Comparative electrophysiology and receptor-binding studies are used to characterise oxiracetam&#8217;s relative potency against other racetam-family compounds at these targets. Independently third-party HPLC-tested; COA available per batch.<\/span>\t\t\t\t\t<\/div>\n<div>\n<h2>FAQ<\/h2>\n<div>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>How does oxiracetam&#8217;s structural modification relative to piracetam relate to its proposed mechanism of action?<\/span><\/p>\n<\/summary>\n<div>\n<p>Oxiracetam differs from piracetam by a hydroxyl group at the 4-position of the shared pyrrolidinone ring.<\/p>\n<p>This structural modification is studied for its influence on receptor-binding affinity and pharmacokinetic properties relative to the parent compound, within structure-activity relationship research mapping how substitutions on the racetam core scaffold alter target engagement at glutamatergic and cholinergic systems.<\/p>\n<p>Comparative binding and functional assays against piracetam and other racetam-family compounds are the standard approach for characterising this relationship.<\/p>\n<\/div>\n<\/details>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>What electrophysiological methods are used to study oxiracetam&#8217;s effects on AMPA receptor signaling?<\/span><\/p>\n<\/summary>\n<div>\n<p>Patch-clamp electrophysiology in cultured neurons or brain slice preparations is the standard method for characterising compound effects on AMPA receptor-mediated excitatory postsynaptic currents (EPSCs), allowing researchers to quantify changes in current amplitude, kinetics, or desensitization properties following oxiracetam exposure. These functional electrophysiological readouts are typically paired with receptor-binding assays to distinguish direct receptor modulation from indirect effects on presynaptic glutamate release.<\/p>\n<\/div>\n<\/details>\n<details>\n<summary>\n\t\t\t\t\t\t\t\t\t\t<span>What is the research rationale for studying oxiracetam&#8217;s combined effects on cholinergic and glutamatergic systems?<\/span><\/p>\n<\/summary>\n<div>\n<p>Because oxiracetam has been investigated for activity at both glutamatergic AMPA receptors and cholinergic high-affinity choline uptake, it serves as a research tool for studying potential crosstalk or convergent downstream effects between these two neurotransmitter systems on cognitive-relevant cellular endpoints (such as long-term potentiation models). Researchers isolating which pathway drives a given experimental outcome typically use selective antagonists for one system (e.g. an AMPA receptor antagonist) while measuring oxiracetam&#8217;s effects on the other, to determine pathway dependence.<\/p>\n<\/div>\n<\/details><\/div>\n<\/p><\/div>\n<\/div>\n<\/section>\n","protected":false},"excerpt":{"rendered":"<p>Oxiracetam is a hydroxylated pyrrolidinone derivative within the racetam structural class, distinguished from piracetam by a 4-hydroxy substitution on the pyrrolidinone ring.<\/p>\n<p>Darreichungsform: Oxiracetam \u2013 Powder, 50 grams.<\/p>\n<p class=\"nm-research-disclaimer\">Nur f\u00fcr die Laborforschung. Nicht zur Anwendung bei Menschen oder Tieren.<\/p>\n<p class=\"nm-catalog-image-note\"><small>Mit KI erstellte illustrative Verpackung.<\/small><\/p>\n","protected":false},"featured_media":1008,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[24],"product_tag":[],"nm_classification":[],"class_list":["post-855","product","type-product","status-publish","has-post-thumbnail","product_cat-cognitive-health-nootropics","first","instock","shipping-taxable","product-type-simple"],"_links":{"self":[{"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/product\/855","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/comments?post=855"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/media\/1008"}],"wp:attachment":[{"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/media?parent=855"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/product_brand?post=855"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/product_cat?post=855"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/product_tag?post=855"},{"taxonomy":"nm_classification","embeddable":true,"href":"https:\/\/novameds.health\/de\/wp-json\/wp\/v2\/nm_classification?post=855"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}